ArticleJournal of substance abuse treatment2017
Retention in buprenorphine treatment is associated with improved HCV care outcomes.
Article in Journal of substance abuse treatment, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 37 citations in OpenAlex.
- Nonadherence to Ledipasvir/Sofosbuvir Did Not Predict Sustained Virologic Response in a Randomized Controlled Trial of Human Immunodeficiency Virus/Hepatitis C Virus Coinfected Persons Who Use Drugs.The Journal of infectious diseases · 2022Trial
- Hepatitis C Treatment in Kentucky Medicaid Recipients with Concurrent Opioid Use Disorder: A Cross-Sectional Study.Journal of general internal medicine · 2025Article
- Bridging the gap: Addressing disparities in hepatitis C screening, access to care, and treatment outcomes.World journal of hepatology · 2024Review
- Temporal trends in HCV treatment uptake and success among people who inject drugs in Baltimore, MD since the introduction of direct acting antivirals.Drug and alcohol dependence · 2023Article
- Implementing a peer-supported, integrated strategy for substance use disorder care in an outpatient infectious disease clinic is associated with improved patient outcomes.The International journal on drug policy · 2023Article
- State Policy and the Breadth of Buprenorphine-Prescriber Networks in Medicaid Managed Care.Medical care research and review : MCRR · 2023Article
- Exploring the Association of State Policies and the Trajectories of Buprenorphine Prescriber Patient Caseloads.Substance abuse · 2023Article
- Evaluation of the Impact of HIV Serostatus on the Hepatitis C Virus Care Cascade and Injection Drug Use Among Persons Initiating Medication Treatment for Opioid Use Disorder.Open forum infectious diseases · 2022Article
- Medicaid Managed Care: Access To Primary Care Providers Who Prescribe Buprenorphine.Health affairs (Project Hope) · 2022Article
- Mobile low-threshold buprenorphine integrated with infectious disease services.Journal of substance abuse treatment · 2022Article
- Comparing telemedicine to in-person buprenorphine treatment in U.S. veterans with opioid use disorder.Journal of substance abuse treatment · 2022Article
- Barriers and facilitators of HIV and hepatitis C care among people who inject drugs in Nairobi, Kenya: a qualitative study with peer educators.Harm reduction journal · 2021Article
- Buprenorphine prescriber monthly patient caseloads: An examination of 6-year trajectories.Drug and alcohol dependence · 2021Article
- Cascade of Hepatitis C Virus Care Among Patients With Substance Use Disorders.American journal of preventive medicine · 2021Article
- Prevalence and Medication Treatment of Opioid Use Disorder Among Primary Care Patients with Hepatitis C and HIV.Journal of general internal medicine · 2021Observational
- Buprenorphine dispensing in an epicenter of the U.S. opioid epidemic: A case study of the rural risk environment in Appalachian Kentucky.The International journal on drug policy · 2020Article
- "Caballo": risk environments, drug sharing and the emergence of a hepatitis C virus epidemic among people who inject drugs in Puerto Rico.Harm reduction journal · 2020Article
- Hepatitis C treatment uptake among people who inject drugs in the oral direct-acting antiviral era.Liver international : official journal of the International Association for the Study of the Liver · 2020Article
- Identification and Management of Opioid Use Disorder in Primary Care: an Update.Current psychiatry reports · 2020Review
- Optimizing HIV prevention and treatment outcomes for persons with substance use in Central Asia: what will it take?Current opinion in HIV and AIDS · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
Persons who inject drugs, most of whom are opioid dependent, comprise the majority of the HCV infected in the United States. As the national opioid epidemic unfolds, increasing numbers of people are entering the medical system to access treatment for opioid use disorder, specifically with buprenorphine. Yet little is known about HCV care in patients accessing buprenorphine-based opioid treatment. We sought to determine the HCV prevalence, cascade of care, and the association between patient characteristics and completion of HCV cascade of care milestones for patients initiating buprenorphine treatment. We reviewed electronic health records of all patients who initiated buprenorphine treatment at a primary-care clinic in the Bronx, NY between January 2009 and January 2014. Of the 390 patients who initiated buprenorphine treatment, 123 were confirmed to have chronic HCV infection. The only patient characteristic associated with achieving HCV care milestones was retention in opioid treatment. Patients retained (vs. not retained) in buprenorphine treatment were more likely to be referred for HCV specialty care (63.1% vs. 34.0%, p<0.01), achieve an HCV-specific evaluation (40.8% vs. 21.3%, p<0.05), be offered HCV treatment (22.4% vs. 8.5%, p<0.05), and initiate HCV treatment (9.2% vs. 6.4%, p=0.6). Given the current opioid epidemic in the US and the growing number of people receiving buprenorphine treatment, there is an unprecedented opportunity to access and treat persons with HCV, reducing HCV transmission, morbidity and mortality. Retention in opioid treatment may improve linkage and retention in HCV care; innovative models of care that integrate opioid drug treatment with HCV treatment are essential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.